Myovant Sciences Ltd
$
9.31
0 (0%)
| Volume: | 114,222 | Avg Vol (1m): | 376,772 |
| Market Cap $: | 834.37 Mil | Enterprise Value $: | 777.68 Mil |
| P/E (TTM): | 0.00 | P/B: | 150.18 |
| Earnings Power Value | 0 |
| Net Current Asset Value | -0.03 |
| Tangible Book | 0.06 |
| Projected FCF | 0 |
| Median P/S Value | 0 |
| Graham Number | 0 |
| Peter Lynch Value | 0 |
| DCF (FCF Based) | 0 |
| DCF (Earnings Based) | 0 |
1Y (-%)
Manual of Stocks™ Web
Financial Strength : 4/10
GuruFocus Financial Strength Rank measures how strong a company's financial situation is . It is based on these factors
1. The debt burden that the company has as measured by its Interest coverage (current year).
2. Debt to revenue ratio. The lower, the better
3. Altman Z-score.
A company ranks high with financial strength is likely to withstand any business slowdowns and recessions.
| Current | vs industry | vs history | |
|---|---|---|---|
| Cash-to-Debt | 1.57 |
Cash-To-Debt ranked
lower than
66.33%
of
1078
companies
in the
Biotechnology
industry.
Industry Max: 20856.43, Med: 64.02, Min: 0.01
MYOV:
1.57
Ranked among companies with meaningful Cash-To-Debt only.
|
Cash-To-Debt range over the past 10 years
Min: 1.57, Med: 2.49, Max: 10000
Current: 1.57
|
| Debt-to-Equity | 22.93 |
Debt-to-Equity ranked
lower than
77.40%
of
500
companies
in the
Biotechnology
industry.
Industry Max: 35.66, Med: 0.28, Min: 0.01
MYOV:
22.93
Ranked among companies with meaningful Debt-to-Equity only.
|
Debt-to-Equity range over the past 10 years
Min: 1.16, Med: 12.04, Max: 22.93
Current: 22.93
|
| Debt-to-EBITDA | -0.38 |
Debt-to-EBITDA ranked
lower than
100.00%
of
196
companies
in the
Biotechnology
industry.
Industry Max: 1208.58, Med: 2.04, Min: 0.01
MYOV:
-0.38
Ranked among companies with meaningful Debt-to-EBITDA only.
|
Debt-to-EBITDA range over the past 10 years
Min: -0.38, Med: -0.34, Max: -0.31
Current: -0.38
|
| Piotroski F-Score | 1 |
0
1
2
3
4
5
6
7
8
9
| |
| Altman Z-Score | -5.48 |
DISTRESS
GREY
SAFE
| |
Profitability & Growth : 3/10
GuruFocus Profitability Rank ranks how profitable a company is and how likely the company's business will stay that way.
| Current | vs industry | vs history | |
|---|---|---|---|
| ROE % | -613.19 |
ROE ranked
lower than
88.88%
of
989
companies
in the
Biotechnology
industry.
Industry Max: 326.78, Med: -42.82, Min: -100794.12
MYOV:
-613.19
Ranked among companies with meaningful ROE only.
|
ROE range over the past 10 years
Min: -1300.67, Med: -140.1, Max: -100.2
Current: -613.19
|
| ROA % | -167.56 |
ROA ranked
lower than
90.59%
of
1084
companies
in the
Biotechnology
industry.
Industry Max: 224.74, Med: -34.77, Min: -3751.92
MYOV:
-167.56
Ranked among companies with meaningful ROA only.
|
ROA range over the past 10 years
Min: -187.31, Med: -94.13, Max: -90.07
Current: -167.56
|
| ROC (Joel Greenblatt) % | -16750.38 |
ROC (Joel Greenblatt) ranked
lower than
88.42%
of
1036
companies
in the
Biotechnology
industry.
Industry Max: 641137.84, Med: -521.46, Min: -3427023.81
MYOV:
-16750.38
Ranked among companies with meaningful ROC (Joel Greenblatt) only.
|
ROC (Joel Greenblatt) range over the past 10 years
Min: -18435.76, Med: -15804.67, Max: -12941.35
Current: -16750.38
|
» MYOV's 30-Y Financials
Financials (Next Earnings Date: 2019-08-07)
Guru Trades Click for details
Guru Trades in
SEC Filings
Gurus Latest Trades with NYSE:MYOV
» Interactive Chart
Peter Lynch Chart
Business Description
| Industry | Biotechnology » Biotechnology |
| Compare | XPAR:ALCLS NAS:GTHX NAS:ITCI ASX:SRX NAS:DVAX NAS:ARMO NAS:TGTX XPAR:DBV NAS:ASMB NAS:CTMX NAS:WVE NYSE:CO NAS:APLS TSXV:CRON OSTO:HMED SHSE:600200 NAS:RVNC NAS:ADAP NAS:ACOR NAS:BOLD |
| Traded in other countries | 71M.Germany |
| Address | 11-12 St. James’s Square, Suite 1, 3rd Floor, London, GBR, SW1Y 4LB |
| Myovant Sciences Ltd is a clinical-stage biopharmaceutical company. The Company is focused on developing and commercializing therapies for women's health diseases and other endocrine-related disorders. Its product candidate is relugolix. | |
Ratios
| Current | vs industry | vs history | |
|---|---|---|---|
| PB Ratio | 150.18 |
PB Ratio ranked
lower than
94.07%
of
962
companies
in the
Biotechnology
industry.
Industry Max: 2236, Med: 4.1, Min: 0.05
MYOV:
150.18
Ranked among companies with meaningful PB Ratio only.
|
PB Ratio range over the past 10 years
Min: 0, Med: 0, Max: 200.48
Current: 150.18
|
| EV-to-EBIT | -2.94 |
EV-to-EBIT ranked
lower than
100.00%
of
261
companies
in the
Biotechnology
industry.
Industry Max: 4391.42, Med: 22.17, Min: 0.02
MYOV:
-2.94
Ranked among companies with meaningful EV-to-EBIT only.
|
EV-to-EBIT range over the past 10 years
Min: -21.98, Med: 0, Max: 0
Current: -2.94
|
| EV-to-EBITDA | -2.95 |
EV-to-EBITDA ranked
lower than
100.00%
of
281
companies
in the
Biotechnology
industry.
Industry Max: 28816.43, Med: 18.08, Min: 0.02
MYOV:
-2.95
Ranked among companies with meaningful EV-to-EBITDA only.
|
EV-to-EBITDA range over the past 10 years
Min: -21.98, Med: 0, Max: 0
Current: -2.95
|
| Current Ratio | 2.32 |
Current Ratio ranked
lower than
62.85%
of
1074
companies
in the
Biotechnology
industry.
Industry Max: 3987.61, Med: 4.46, Min: 0.01
MYOV:
2.32
Ranked among companies with meaningful Current Ratio only.
|
Current Ratio range over the past 10 years
Min: 2.32, Med: 3.09, Max: 10.04
Current: 2.32
|
| Quick Ratio | 2.32 |
Quick Ratio ranked
lower than
60.34%
of
1074
companies
in the
Biotechnology
industry.
Industry Max: 3987.61, Med: 4.18, Min: 0.01
MYOV:
2.32
Ranked among companies with meaningful Quick Ratio only.
|
Quick Ratio range over the past 10 years
Min: 2.32, Med: 3.09, Max: 10.04
Current: 2.32
|
Dividend & Buy Back
| Current | vs industry | vs history |
|---|
Valuation & Return
| Current | vs industry | vs history | |
|---|---|---|---|
| Price-to-Tangible-Book | 155.17 |
Price-to-Tangible-Book ranked
lower than
90.72%
of
894
companies
in the
Biotechnology
industry.
Industry Max: 800, Med: 5.32, Min: 0.05
MYOV:
155.17
Ranked among companies with meaningful Price-to-Tangible-Book only.
|
Price-to-Tangible-Book range over the past 10 years
Min: 4.24, Med: 34.36, Max: 367.23
Current: 155.17
|
| Earnings Yield (Joel Greenblatt) % | -34.02 |
Earnings Yield (Greenblatt) ranked
lower than
61.52%
of
1081
companies
in the
Biotechnology
industry.
Industry Max: 5000, Med: -7.73, Min: -10000
MYOV:
-34.02
Ranked among companies with meaningful Earnings Yield (Greenblatt) only.
|
Earnings Yield (Greenblatt) range over the past 10 years
Min: -46.78, Med: 0, Max: 0
Current: -34.02
|
More Statistics
Analyst Estimate
Piotroski F-Score Details
| Piotroski F-Score | 1 |
| Positive ROA | N |
| Positive CFROA | N |
| Higher ROA yoy | N |
| CFROA > ROA | Y |
| Lower Leverage yoy | N |
| Higher Current Ratio yoy | N |
| Less Shares Outstanding yoy | N |
| Higher Gross Margin yoy | N |
| Higher Asset Turnover yoy | N |